{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:35:29Z","timestamp":1789425329176,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"43","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.vaccine.2017.08.071","type":"journal-article","created":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T22:00:15Z","timestamp":1504562415000},"page":"5918-5923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Biodistribution and safety of a live attenuated tetravalent dengue vaccine in the cynomolgus monkey"],"prefix":"10.1016","volume":"35","author":[{"given":"Guillaume","family":"Ravel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Mantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Silvano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Rogue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Burdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.vaccine.2017.08.071_b0005","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMra1110265","article-title":"Dengue","volume":"366","author":"Simmons","year":"2012","journal-title":"Engl J Med"},{"key":"10.1016\/j.vaccine.2017.08.071_b0010","unstructured":"World Health Organization. Dengue - Guidelines for diagnosis, Treatment, prevention and control [New edition, October 2009]. Geneva, World Health Organization. (Also available at: http:\/\/www.who.int\/tdr\/publications\/documents\/dengue-diagnosis.pdf)."},{"key":"10.1016\/j.vaccine.2017.08.071_b0015","unstructured":"World Health Organization. Dengue and severe dengue [factsheet no. 117, revised January 2012]. Geneva, World Health Organization. (Also available at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs117\/en\/)."},{"key":"10.1016\/j.vaccine.2017.08.071_b0020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-med-091014-090848","article-title":"Vaccination against dengue: challenges and current developments","volume":"67","author":"Guy","year":"2016","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.vaccine.2017.08.071_b0025","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/v4010062","article-title":"Animal models of dengue virus infection","volume":"4","author":"Zompi","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2017.08.071_b0030","unstructured":"World Health Organization. Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). Geneva, WHO Expert Committee on Biological Standardization. WHO Technical Report Series No. 979: Annex 2, 2011. p. 53\u2013135. (Also available at: http:\/\/www.who.int\/biologicals\/areas\/vaccines\/TRS_979_Annex_2.pdf)."},{"key":"10.1016\/j.vaccine.2017.08.071_b0035","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1128\/JVI.78.9.4761-4775.2004","article-title":"Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates","volume":"78","author":"Guirakhoo","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.071_b0040","unstructured":"World Health Organization. Guidelines on Nonclinical Evaluation of Vaccines. Geneva, WHO Expert Committee on Biological Standardization. WHO Technical Report Series No. 927: Annex 1, 2005. p. 31\u201363. (Also available at: http:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/vaccines\/nonclinical_evaluation\/ANNEX%201Nonclinical.P31-63.pdf)."},{"key":"10.1016\/j.vaccine.2017.08.071_b0045","series-title":"Fields Virology","first-page":"1043","article-title":"Flaviviruses","author":"Burke","year":"2001"},{"key":"10.1016\/j.vaccine.2017.08.071_b0050","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.08.071_b0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2017.08.071_b0060","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1386-6532(09)70290-2","article-title":"Immunogenicity of sanofi pasteur tetravalent dengue vaccine","volume":"46","author":"Guy","year":"2009","journal-title":"J Clin Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2017.08.071_b0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jviromet.2008.03.026","article-title":"Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines","volume":"151","author":"Mantel","year":"2008","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2017.08.071_b0070","unstructured":"European Communities (EC) (1986). Council Directive 86\/609\/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Off. J. Eur. Communities, L 358, 18\/12\/1986, 1\u201328."},{"key":"10.1016\/j.vaccine.2017.08.071_b0075","unstructured":"Organisation for Economic Co-operation and Development. Principles on good laboratory practice (as revised in 1997). Paris: OECD; 1998. (Series on principles of GLP and compliance monitoring No.1, ENV\/MC\/CHEM(98)17)."},{"issue":"50","key":"10.1016\/j.vaccine.2017.08.071_b0080","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1016\/j.vaccine.2008.08.052","article-title":"Vaccine injection technique and reactogenicity\u2013evidence for practice","volume":"26","author":"Petousis-Harris","year":"2008","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.vaccine.2017.08.071_b0085","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0601932103","article-title":"A live, attenuated recombinant West Nile virus vaccine","volume":"103","author":"Monath","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.08.071_b0090","unstructured":"World Health Organization. Recommendations to assure the quality, safety and efficacy of live attenuated Yellow Fever vaccines. Geneva, WHO Expert Committee on Biological Standardization. WHO Technical Report Series No. 978: Annex 5, 2013. p. 241\u2013314. (Also available at: http:\/\/apps.who.int\/biologicals\/areas\/vaccines\/TRS_978_Annex_5.pdf)."},{"issue":"2","key":"10.1016\/j.vaccine.2017.08.071_b0095","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1006\/viro.2002.1704","article-title":"High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis","volume":"305","author":"Wang","year":"2003","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2017.08.071_b0100","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/315215","article-title":"Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity","volume":"181","author":"Vaughn","year":"2000","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2017.08.071_b0105","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1086\/382280","article-title":"Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand","volume":"189","author":"Endy","year":"2004","journal-title":"J Infect Dis"},{"issue":"9853","key":"10.1016\/j.vaccine.2017.08.071_b0110","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.08.071_b0115","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/viro.2002.1462","article-title":"Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates","volume":"298","author":"Guirakhoo","year":"2002","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.vaccine.2017.08.071_b0120","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0092-1157(87)80003-3","article-title":"The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination","volume":"15","author":"Levenbook","year":"1987","journal-title":"J Biol Stand"},{"issue":"7","key":"10.1016\/j.vaccine.2017.08.071_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004821","article-title":"Safety overview of a recombinant live-attenuated tetravalent dengue vaccine: pooled analysis of data from 18 clinical trials","volume":"10","author":"Gailhardou","year":"2016","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17311696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17311696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T08:45:20Z","timestamp":1531557920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17311696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":25,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0264410X17311696"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.071","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biodistribution and safety of a live attenuated tetravalent dengue vaccine in the cynomolgus monkey","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}